Finance Watch: Theravance Eliminates Debt In $1.1bn Trelegy Royalty Sell-Off
Also, Ultragenyx Leverages Crysvita Royalties In $500m Deal
Executive Summary
Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.
You may also be interested in...
CytomX Bounces Back From Trial Setback With Regeneron Bispecific Antibody Partnership
The US biotech has nabbed a deal with Regeneron to develop bispecific cancer therapies by combining their respective technology platforms, getting $30m upfront in a positive twist of fate following a recent clinical trial challenge.
Adverum Makes Job Cuts To Advance Wet AMD Gene Therapy
The California-based biotech is reducing its workforce to help finance a Phase II study of Ixo-vec, its eye gene therapy which has been blighted by safety concerns.
Finance Watch: Resilience Raises $625m, Bringing New Cash To $1.2bn
The biomanufacturing firm National Resilience has raised more than $2bn in venture capital and millions more in fees from government and industry contracts since 2020. Also, Code Biotherapeutics raised $75m in series A cash, Concert grossed $66.4m and Amarin is cutting US jobs.